

SPECIALTY QUANTITY LIMIT PROGRAM

TIBSOVO (ivosidenib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tibsovo 250 mg tablet	60 per 30 days	500 mg (two 250 mg tablets) once daily Dose reduction: <ul style="list-style-type: none"> • For use with strong CYP3A4 inhibitors: 250 mg once daily • For QTc interval greater than 500 msec: Interrupt and resume at 250 mg once daily when QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec • For other Grade 3 or higher toxicity: Interrupt and resume at 250 mg once daily if toxicity resolves to Grade 2 or lower

III. REFERENCES

1. Tibsovo [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc; July 2018.